Comparative Pharmacology
Head-to-head clinical analysis: BRONKOMETER versus MAXAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOMETER versus MAXAIR.
BRONKOMETER vs MAXAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Category C
Category C
Bronchodilator
Bronchodilator